Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Dru...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and Dru...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21;153:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Vascul Pharmacol. 2023 Oct 21;153:107238. doi: 10.1016/j.vph.2023.107238. Online ahead of print.ABSTRACTInflammation and hyperlipidemia act synergistically to drive atherosclerotic progression. Multiple randomized trials now demonstrate that "lower is better" not only for LDLC, but also for hsCRP. Recent data among statin treated patients indicates that residual inflammatory risk is a stronger determinant of recurrent events than residual cholesterol risk. Based on trial data demonstrating a 31% reduction in events with minimal side effects, low-dose colchicine (0.5 mg daily) has been approved by the United States Food and...
Source: Vascular Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Authors: Paul M Ridker Source Type: research
Cancers, Vol. 15, Pages 5097: Dose Consideration of Lenvatinib & rsquo;s Anti-Cancer Effect on Hepatocellular Carcinoma and the Potential Benefit of Combined Colchicine Therapy
Conclusions: Lenvatinib does not show a dose-dependent anti-cancer effect on HCC. Combined colchicine and lenvatinib can promote the total anti-cancer effects on HCC. (Source: Cancers)
Source: Cancers - October 22, 2023 Category: Cancer & Oncology Authors: Zu-Yau Lin Ming-Lun Yeh Po-Cheng Liang Po-Yao Hsu Chung-Feng Huang Jee-Fu Huang Chia-Yen Dai Ming-Lung Yu Wan-Long Chuang Tags: Article Source Type: research
